Summary Regional chemotherapy is commonly used to treat patients with colorectal liver metastases. However, improvement in survival has still not been demonstrated. Cytotoxic loaded albumin microspheres for arterial administration have been described as a means of improving the therapeutic index, but their distribution depends upon the prevailing pattern of arterial blood-flow at the time of injection. In this study, the ability of the vasoactive drug angiotensin II to target arterially injected microspheres to colorectal liver metastases is assessed in nine patients using scintigraphic planar and tomographic imaging.
Post-mortem studies have shown that up to 70% of patients dying after a potentially curative resection for colorectal cancer, die with liver metastases. The prognosis of patients with colorectal liver metastases is generally poor, survival being in the range of 3 to 9 months (Woods, 1984; Nielsen et al., 1971) .
Surgical resection of colorectal hepatic metastases may be effective in patients with limited disease (Bradpiece et al., 1987) , but may not be feasible in the majority of patients where multiple tumours are present. Although some recent studies of combined systemic 5 fluorouracil and folinic acid or interferon show promising results (O'Connell, 1989 ; Kerr, 1989; Wadler et al., 1989) , conventional systemic chemotherapy has been associated with poor response rates. Attention has therefore turned to regional chemotherapy.
It is known that established colorectal liver metastases receive their blood supply from the hepatic artery and the administration of anti-cancer drugs via an indwelling hepatic arterial catheter is now widely practised (Ridge et al., 1987) . Unfortunately, although the tumour response rates may increase when chemotherapeutic agents are administered intraarterially rather than systemically (Berger, 1981) a significant increase in survival among treated patients has not been demonstrated by randomised controlled trial (Malik & Wrigley, 1988) .
Novel chemotherapeutic drug delivery systems including cytotoxic loaded or radioactive microspheres for administration by the arterial route, have been developed. We have previously described cytotoxic loaded albumin microspheres (diameter 20-40IAm) which are trapped in the liver when injected into the hepatic artery (McArdle et al., 1988; Willmott et al., 1985) , the drug being released as the microsphere degrades. However intra-arterial injection of such particles results in their unselective distribution throughout the liver, microsphere concentration within different regions of the organ being dependent upon the prevailing distribution of arterial blood-flow. However, if drug-loaded microspheres could be targeted into tumours, the therapeutic advantage might be greatly improved and systemic and hepatocellular toxicity reduced. Such a mechanism was described in 1985 by Sasaki and co-workers who reported the effect of angiotensin II on tumour blood-flow in patients with neoplastic liver disease. Angiotensin II produces temporary vasoconstriction in normal liver arterioles. Tumour vasculature, being immature, is unable to vasoconstrict because it lacks both an adrenergic nerve supply and smooth muscle in the vessel wall. For a short period during a regional angiotensin II infusion therefore, a situation exists where particles administered by bolus injection might be targeted effectively towards tumours.
We have previously attempted to quantitate the ability of angiotensin II to concentrate arterially administered microspheres within hepatic tumours, using a double isotope technique and biopsies obtained at laparotomy (Goldberg et al., 1990a) . Such techniques might be open to a number of errors. In particular, sampling differences and the effects of general anaesthesia on liver blood-flow are difficult to control. The present study was performed to gain a broader assessment of tumour targeting within the whole liver in conscious patients.
Method
The targeting ability of angiotensin II was estimated in 11 patients with biopsy-confirmed advanced colorectal hepatic metastases and indwelling hepatic arterial perfusion catheters, using standard scintographic techniques. Each patient had three scintigraphic studies of the liver completed with single photon emission computed tomography (SPECT):
(a) After an intravenous injection of albumin colloid. The studies were performed in random order, at least 3 days apart and completed within a 2 week period. The albumin colloid study was performed to localise tumours and to assess the extent of liver involvement by metastatic disease. Aquisition of the SPECT images was commenced approximately 15 min after intravenous injection of 80 MBq of 'Tc albumin colloid.
The other two studies were performed by hepatic arterial perfusion scintigraphy (HAPS). Albumin microsphereswith 80 MBq of pertechnetate (99"Tc MSA) were used.
Immediately before arterial injection, the vial of microspheres was vortexed and the dose drawn up into a glass syringe (Goldberg et al., 1987) . After particle administration, the syringe was flushed twice with normal saline, and the catheter heparinised to maintain patency. In one 991Tc MSA study there was no additional patient preparation. In the other, microsphere administration was performed immediately after a 100 s intra-arterial infusion of angiotensin II at a rate of 0pggmin-'.
All studies were performed using an IGE 400AT tomographic gamma camera with a low energy parallel collimator, and the images stored on a dedicated computer (MAPS 2000, Link Analytical Ltd). Patients were positioned supine on the tomography couch with the arms behind the head. For all three studies, SPECT aquisition of 64 twenty-second images at 64 pixel resolution were taken of the liver over 3600. Each image was corrected with a uniformity flood-field of 8 x 106 counts, acquired prior to the study to accommodate for inherent gamma camera non-uniformities. The X ADC offset was adjusted to give a mean error of less than ± 0.16 pixels (1 mm) for a 360°arc.
The tomographic studies were reconstructed using a Data General Nova computer with commercial software (Link Analytical Ltd) in which the standard ramp filter was modified by a generalised Hamming window function with a constant equal to 0.54. No correction was made for attenuation or scatter. Since the same areas of tumour and liver were used in the different studies on any one patient, any errors arising from this would cancel out when enhancement ratios were calculated.
Reconstructed transverse slices from the three scintigraphic studies for each patient were aligned with each other as follows. By comparing the planar anterior images from the tomographic aquisitions, corresponding transverse slices were identified. The slices were aligned in the remaining two dimensions by comparing five corresponding transverse slices from each study. Alignment was achieved for each slice by moving the image from one study relative to a region of interest drawn on the other, until all three studies were in correct registration relative to one another. The average values of the relative x and y shifts for the five sections were then taken as the definitive amount for shifting all the slices of a study, it being assumed that the same movement was appropriate for each slice of a transverse set. The movement process resulted in three sets of transverse slices per patient which could be superimposed to within a single pixel mismatch in any dimension. Relative rotation of iiages was not necessary.
To check the alignment and also to assess the localisation of microspheres in tumour, images from the colloid study and from each of the microsphere studies were combined on the computer and displayed in different colours using the commercial software (Figures 1-4) .
Since albumin colloid is taken up by normal liver tissue while miscrospheres administered via the hepatic artery often concentrate in tumour regions, a true whole liver outline was obtained by superimposing colloid and microsphere images. The intensities of the three studies were adjusted before creating a composite image in order to visualise all of the components. The whole liver outline was defined on the composite image for each slice.
Because albumin colloid is taken up by functioning hepatocytes, tumour regions are seen as cavitations within the liver image (Figures 1 and 2) . On each slice of the albumin colloid study regions of interest were drawn to define normal liver and tumour areas. Tumour regions were defined as being regions of low uptake on the albumin col- loid slice. The remainder of the organ was taken to be normal liver parenchyma. A region of interest of approximately five pixels diameter was defined over an area of uniformly high uptake on each colloid slice and used as a sample of normal liver to quantitate the activity ratios of tumour and normal liver.
The regions as defined above on a slice of the albumin colloid scan (whole-liver, normal liver, tumours) were superimposed on the corresponding slices of both microsphere studies (Figure 3) . The activity within these regions was used to estimate the ratio of activity in normal and tumour regions of both the simple and the angiotensin II enhanced microsphere studies. The improvement with angiotensin II was estimated as the ratio of these two tumour:normal count density ratios. Every tumour was assessed within the liver at its largest diameter on transverse reconstruction. The tumour diameter was defined as the diameter of a circle with the same area as the actual region of interest drawn around the tumour.
Results
Two patients had markedly hypervascular tumours and the counts in their normal liver regions on one or both microsphere studies were exceedingly low or at background level, irrespective of whether angiotenin II had been used. The tumour:normal ratio before angiotensin II in these two patients was 30:1 and infinity respectively. Sufficient normal liver counts could not be obtained in either patient even when the 'normal' liver sample was taken to be the whole slice less the tumour regions, after angiotensin II had been given.
In the remaining nine patients, 48 tumours were individually assessed, ranging in diameter from approximately 4.5-10 cm, as measured from the colloid images, thereby avoiding the problems of quantitating deposits at the limits of resolution of the system. In Figure 5 , the ratio of activity between tumour and normal liver can be seen for each tumour, before and after angiotensin II. Figure 6 demonstrates the targeting power of angiotensin II in all 48 tumours. Table I shows the median value of tumour:normal ratio for each patient before and after angiotensin II and also the median improvement in tumour:normal ratio for each patient. The median tumour:normal ratio before angiotensin II was 3.4:1 (range 1.3-6.0) among the nine patients, whereas the median ratio after angiotensin II was 7.3:1 (range 1.5-8.8). This difference was significant by the Wilcoxon test for paired samples (P<0.05). The median improvement in tumour:normal ratio of microsphere bound activity after angiotensin II was by a factor of 1.8 (range 0.9-3.4). No relationship was found between the success in targeting with angiotensin II and tumour diameter.
In addition to the 48 tumours described above, there were three with hypervascular shells and relatively hypovascular cores, all of which were more than 5 cm in diameter (Figure 4) . Although the cores were hypovascular relative to the rim, they were always hypervascular relative to the normal liver. These were difficult to quantitate with any degree of certainty because the resolution of the image acquisition system was not sufficient to clearly define the boundary between the core and shell regions within the tumour. However, within these three tumours, the count density when angiotensin II was used appeared to increase to a greater extent within the central hypovascular core than within the shell region Figure 3 Computer aligned composite of the albumin colloid slice (green) and the angiotensin II enhanced microsphere study (red) (from Figure 2) , illustrating the reciprocity of the two scans and accurate tumour targeting.
(median core: rim ratio of enhancement ratios was 1.26, range 0.93-1.49; six readings).
Discussion
The technique for defining the regions of interest for tumour and normal liver tissue was crucial to this analysis of targeting. The definition of the whole liver outline was straightforward. There are, however, potential pitfalls in the definition of tumour and normal liver regions which merit further discussion.
During image reconstruction, no correction was made for attenuation or scatter but both of these will have some effect on the measured count densities of the tumour and normal regions which we defined. In particular, quantitation of the 'hypovascular' core of a tumour with a markedly hypervascular rim may overestimate the activity within the core. The proximity of the selected region of normal tissue to tumours, and the positions of both normal and tumour regions within the liver must also be considered. In patients with a large volume of liver affected by metastatic disease, or with diffuse tumour, an area of apparently normal liver which was not close to tumour was sometimes difficult to select.
The proximity of normal liver tissue to tumour is also worthy of consideration on physical and physiological grounds. If the selected normal region is very close to a tumour, it may contain counts due to gamma rays scattered from the tumour area or due to artifacts from the back projection process. This may result in the generation of a significant background level. This would have the effect of increasing the counts in the normal region close to a tumour, thereby reducing the ratio of activity in tumour to that in normal liver. These considerations would suggest that a normal region should not be selected immediately adjacent to tumour regions when possible. However, if the normal region were at the surface of the liver and the tumour regions deeper within the organ, the effect of attenuation by the surrounding tissue would result in a reduced count density for the deeper tumour regions and the tumour:normal ratio would be decreased.
We defined our normal regions close enough to tumour regions so that differences in attenuation did not significantly effect count densities, but where possible, not so close that system where a 'sustained release' mechanism of drug administration is in operation, since toxicity in normal tissues may become problematical with continuing and extended drug exposure.
Potential limitations of the use of cytotoxic loaded microspheres in regional hepatic therapy include an increase in arterio-venous shunting within the organ, causing relative loss of regional advantage as the particles enter the systemicvenous circulation and embolise in the pulmonary tissues. However, we have recently shown that base-line shunting in patients with colorectal liver metastases is low and not significantly increased following the regional administration of a 'therapeutic' dose of microspheres (Goldberg et al., 1990b) . In clinical practice therefore, we have not found arteriovenous shunting to be a problem.
Clearly, this technique will not offer a solution to all patients, since many patients with liver metastases have occult disease elsewhere. However, data from natural history studies suggest that between 20 and 30% of patients with colorectal liver metastases might benefit from hepatic arterial therapy, since this is the proportion of patients in whom disease is thought to be confined to the liver (Welch & Donaldson, 1979; Daly et al., 1985) .
In conclusion, we have demonstrated that angiotensin II significantly increases the uptake of microspheres by tumour in patients with colorectal liver metastases. This is likely to enhance the tumour response to cytotoxic loaded microspheres, and reduce hepatotoxicity. We are currently exploring the use of angiotensin II in association with cytotoxic-loaded microspheres in patients with colorectal liver metastases.
